InvestmentLilly and Boehringer pause $2bn German investments over planned drug-spending curbsThe announcements came almost simultaneously and send a clear signal to policymakers and the industry: both US pharmaceutical group Eli Lilly and German-based Boehringer Ingelheim are calling planned … more ➔
fundraisingOna Therapeutics bags $86.6m Series B for stealth ADC pushBarcelona-based Ona Therapeutics has raised US$86.6m in a Series B financing to advance a new generation of antibody-drug conjugates into clinical development. more ➔
Start-upIngenix raises €13m to scale AI drug development engineWarsaw-based AI biology company Ingenix has raised €13m in a seed-extension financing round led by Sofinnova Partners, with participation from Inovo VC and OTB VC. more ➔
FinancingIMU Biosciences secures US$53m to decode the immune systemLondon-based IMU Biosciences has expanded its Series A financing to more than US$53m (£40m/€46m) in an oversubscribed round, as the company looks to scale its immune-profiling platform and move further … more ➔
clinical dataAbivax delivers Phase 3 ulcerative colitis win, but safety concerns trigger market sell-offParisian Abivax shared positive topline results for its Phase 3 trial in ulcerative colitis. Its investigational oral, first-in-class miR-124 enhancer, dubbed obefazimod, met all primary and secondary … more ➔
Elnur Amikishiyev-stock.adobe.comStart-upA fresh start for Molecular Health: technology core becomes start-up LuceraA restart from within: Molecular Health is becoming Lucera. After years of shifting corporate fortunes, a substantial part of Heidelberg-based Molecular Health is continuing in a new form. An investor … more ➔
clinical dataGreywolf reports early responses with oral ERAP1 inhibitor in solid tumoursOxford-based Greywolf Therapeutics has reported early clinical activity for its first-in-class oral ERAP1 inhibitor GRWD5769 in combination with the anti-PD-1 antibody cemiplimab across six solid tumour … more ➔
oncologyASCO: Immatics posts data on PRAME pipeline ahead of pivotal readoutImmatics has published a series of updates on its PRAME pipeline, using the American Society for Clinical Oncology (ASCO) Annual Meeting to share data on its lead candidate and next-generation progr … more ➔
Clinical trialOculis drops plans for diabetic macular edema drug after Phase III missSwiss ophthalmology biotech Oculis has suffered a major setback for its most advanced ophthalmology programme after two pivotal Phase III trials of OCS-01 eye drops in diabetic macular edema failed to … more ➔
M&AServier buys Edgewise muscular dystrophy business for up to US$2.65bnFrench pharmaceutical group Servier has agreed to acquire sevasemten and the muscular dystrophy business built around it from US biotech Edgewise Therapeutics Inc. in a transaction worth up to US$2.65bn, … more ➔
Elnur Amikishiyev-stock.adobe.com
